pcDNA™5/FRT Vector

Expression vector designed for use with the Flp-In™ System

Catalog Number V6010-20
Revision Date 12 September 2012
Publication Part Number 25-0307
MAN0000131

For Research Use Only. Not for human or animal therapeutic or diagnostic use.
## Contents

Kit Contents and Storage .................................................................................................................iv
Accessory Products ......................................................................................................................v

### Introduction ......................................................................................................................... 1
Overview ......................................................................................................................................... 1

### Methods ............................................................................................................................... 3
Cloning into pcDNA™5/FRT ........................................................................................................ 3
Transfection .................................................................................................................................... 5

### Appendix ............................................................................................................................... 7
Map of pcDNA™5/FRT Vector ....................................................................................................... 7
Features of pcDNA™5/FRT Vector .............................................................................................. 8
pcDNA™5/FRT/CAT Vector .......................................................................................................... 9
Technical Support ......................................................................................................................... 10
Purchaser Notification ................................................................................................................. 10
References .................................................................................................................................... 11
Kit Contents and Storage

Shipping/Storage

The pcDNA™5/FRT Vectors are shipped on wet ice. Upon receipt, store at –20°C.

Kit Contents

The following vectors are provided with pcDNA™5/FRT:

<table>
<thead>
<tr>
<th>Vector</th>
<th>Quantity</th>
<th>Contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>pcDNA™5/FRT</td>
<td>20 μg</td>
<td>40 μL of 0.5 μg/μL pcDNA™5/FRT in 10 mM Tris–HCl, 1 mM EDTA, pH 8.0.</td>
</tr>
<tr>
<td>pcDNA™5/FRT/CAT</td>
<td>20 μg</td>
<td>40 μL of 0.5 μg/μL pcDNA™5/FRT/CAT in 10 mM Tris–HCl, 1 mM EDTA, pH 8.0.</td>
</tr>
</tbody>
</table>

Product Use

For Research Use Only. Not for human or animal therapeutic or diagnostic use.
Accessory Products

Additional products available from Life Technologies are listed below. For more information, visit our website at [www.lifetechnologies.com](http://www.lifetechnologies.com) or contact Technical Support (page 10).

<table>
<thead>
<tr>
<th>Product</th>
<th>Amount</th>
<th>Catalog No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>T7 Promoter Primer</td>
<td>2 μg, lyophilized</td>
<td>N560–02</td>
</tr>
<tr>
<td>Zeocin®</td>
<td>1 g</td>
<td>R250–01</td>
</tr>
<tr>
<td>Hygromycin</td>
<td>1 g</td>
<td>R220–05</td>
</tr>
<tr>
<td>pFRT/lacZeo</td>
<td>20 μg, suspended as 40 μL of 0.5 μg/μL pFRT/lacZeo in 10 mM Tris–HCl, 1 mM EDTA, pH 8.0.</td>
<td>V6015–20</td>
</tr>
<tr>
<td>pFRT/lacZeo2</td>
<td>20 μg, suspended as 40 μL of 0.5 μg/μL pFRT/lacZeo2 in 10 mM Tris–HCl, 1 mM EDTA, pH 8.0.</td>
<td>V6022–20</td>
</tr>
<tr>
<td>pOG44</td>
<td>20 μg, suspended as 40 μL of 0.5 μg/μL pOG44 in 10 mM Tris–HCl, 1 mM EDTA, pH 8.0.</td>
<td>V6005–20</td>
</tr>
<tr>
<td>One Shot® Kit (TOP10 Chemically Competent Cells)</td>
<td>10 reactions</td>
<td>C4040–10</td>
</tr>
<tr>
<td>One Shot® Kit (TOP10 Electrocompetent Cells)</td>
<td>10 reactions</td>
<td>C4040–50</td>
</tr>
<tr>
<td>One Shot® Kit (TOP10 Electrocompetent Cells)</td>
<td>20 reactions</td>
<td>C4040–52</td>
</tr>
</tbody>
</table>

Flp-In™ Expression Vectors

Additional Flp-In™ expression vectors are available from Life Technologies. For more information about the features of each vector, visit our website at [www.lifetechnologies.com](http://www.lifetechnologies.com) or contact Technical Support (page 10).

<table>
<thead>
<tr>
<th>Product</th>
<th>Amount</th>
<th>Catalog No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>pcDNA™5/FRT/V5-His TOPO® TA Expression Kit</td>
<td>1 kit</td>
<td>K6020–01</td>
</tr>
<tr>
<td>pSecTag/FRT/V5-His TOPO® TA Expression Kit</td>
<td>1 kit</td>
<td>K6025–01</td>
</tr>
<tr>
<td>pEF5/FRT/V5 Directional TOPO® Expression Kit</td>
<td>1 kit</td>
<td>K6035–01</td>
</tr>
<tr>
<td>pEF5/FRT/V5-DEST Gateway® Vector Pack</td>
<td>6 μg, supplied as 40 μL of 150ng/μL vector in 10 mM Tris–HCl, 1 mM EDTA, pH 8.0</td>
<td>V6020–20</td>
</tr>
</tbody>
</table>

*Continued on next page*
Accessory Products, continued

Flp-In™ Host Cell Lines

For your convenience, Life Technologies has available several mammalian Flp-In™ host cell lines that stably express the \textit{lacZ-Zeocin®} fusion gene from pFRT/\textit{lacZeo} or pFRT/\textit{lacZeo}2. Each cell line contains a single integrated FRT site as confirmed by Southern blot analysis. The cell lines should be maintained in medium containing Zeocin®. For more information, visit our website at \url{www.lifetechnologies.com} or contact Technical Support (page 10).

<table>
<thead>
<tr>
<th>Cell Line</th>
<th>Amount</th>
<th>Catalog No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flp-In™-293</td>
<td>$3 \times 10^6$ cells, frozen</td>
<td>R750–07</td>
</tr>
<tr>
<td>Flp-In™-CV-1</td>
<td>$3 \times 10^6$ cells, frozen</td>
<td>R752–07</td>
</tr>
<tr>
<td>Flp-In™-CHO</td>
<td>$3 \times 10^6$ cells, frozen</td>
<td>R758–07</td>
</tr>
<tr>
<td>Flp-In™-BHK</td>
<td>$3 \times 10^6$ cells, frozen</td>
<td>R760–07</td>
</tr>
<tr>
<td>Flp-In™-3T3</td>
<td>$3 \times 10^6$ cells, frozen</td>
<td>R761–07</td>
</tr>
<tr>
<td>Flp-In™-Jurkat</td>
<td>$3 \times 10^6$ cells, frozen</td>
<td>R762–07</td>
</tr>
</tbody>
</table>
pcDNA™5/FRT is a 5.1 kb expression vector designed for use with the Flp-In™ System (Catalog nos. K6010-01 and K6010-02) available from Life Technologies. When cotransfected with the pOG44 Flp recombinase expression plasmid into a Flp-In™ mammalian host cell line, the pcDNA™5/FRT vector containing the gene of interest is integrated in a Flp recombinase-dependent manner into the genome. The vector contains the following elements:

- The human cytomegalovirus (CMV) immediate-early enhancer/promoter for high-level constitutive expression of the gene of interest in a wide range of mammalian cells (Andersson et al., 1989; Boshart et al., 1985; Nelson et al., 1987)
- Multiple cloning site with 10 unique restriction sites to facilitate cloning the gene of interest
- Flp Recombination Target (FRT) site for Flp recombinase-mediated integration of the vector into the Flp-In™ host cell line (see next page for more information)
- Hygromycin resistance gene for selection of stable cell lines (Gritz & Davies, 1983)

The control plasmid, pcDNA™5/FRT/CAT, is included for use as a positive control for transfection and expression in the Flp-In™ host cell line of choice.

For more information about the Flp-In™ System, the pOG44 plasmid, and generation of the Flp-In™ host cell line, refer to the Flp-In™ System manual. The Flp-In™ System manual is supplied with the Flp-In™ Complete or Core Systems, but is also available for downloading from our Website (www.lifetechnologies.com) or by contacting Technical Support (see page 10).

The pcDNA™5/FRT vector contains a single FRT site immediately upstream of the hygromycin resistance gene for Flp recombinase-mediated integration and selection of the pcDNA™5/FRT plasmid following cotransfection of the vector (with pOG44) into Flp-In™ mammalian host cells. The FRT site serves as both the recognition and cleavage site for the Flp recombinase and allows recombination to occur immediately adjacent to the hygromycin resistance gene. The Flp recombinase is expressed from the pOG44 plasmid. For more information about the FRT site and recombination, see the next page. For more information about pOG44, refer to the Flp-In™ System manual.

The hygromycin resistance gene in pcDNA™5/FRT lacks a promoter and an ATG initiation codon; therefore, transfection of the pcDNA™5/FRT plasmid alone into mammalian host cells will not confer hygromycin resistance to the cells. The SV40 promoter and ATG initiation codon required for expression of the hygromycin resistance gene are integrated into the genome (in the Flp-In™ host cell line) and are only brought into the correct proximity and frame with the hygromycin resistance gene through Flp recombinase-mediated integration of pcDNA™5/FRT at the FRT site. For more information about the generation of the Flp-In™ host cell line and details of the Flp-In™ System, refer to the Flp-In™ System manual.

Continued on next page
Overview, Continued

Flp Recombinase-Mediated DNA Recombination

In the Flp-In™ System, integration of your pcDNA™5/FRT expression construct into the genome occurs via Flp recombinase-mediated intermolecular DNA recombination. The hallmarks of Flp-mediated recombination are listed below.

• Recombination occurs between specific FRT sites (see below) on the interacting DNA molecules.
• Recombination is conservative and requires no DNA synthesis; the FRT sites are preserved following recombination and there is minimal opportunity for introduction of mutations at the recombination site.
• Strand exchange requires only the small 34 bp minimal FRT site (see below).

For more information about the Flp recombinase and conservative site-specific recombination, refer to published reviews (Craig, 1988; Sauer, 1994).

FRT Site

The FRT site, originally isolated from Saccharomyces cerevisiae, serves as a binding site for Flp recombinase and has been well-characterized (Gronostajski & Sadowski, 1985; Jayaram, 1985; Sauer, 1994; Senecoff et al., 1985). The minimal FRT site consists of a 34 bp sequence containing two 13 bp imperfect inverted repeats separated by an 8 bp spacer that includes an Xba I restriction site (see figure below). An additional 13 bp repeat is found in most FRT sites, but is not required for cleavage (Andrews et al., 1985). While Flp recombinase binds to all three of the 13 bp repeats, strand cleavage actually occurs at the boundaries of the 8 bp spacer region (see figure below) (Andrews et al., 1985; Senecoff et al., 1985).

Experimental Outline

The following table outlines the steps required to clone and express your gene of interest in pcDNA™5/FRT.

<table>
<thead>
<tr>
<th>Step</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Consult the multiple cloning site diagrammed on page 4 to design your cloning strategy.</td>
</tr>
<tr>
<td>2</td>
<td>Ligate your insert into pcDNA™5/FRT and transform into E. coli. Select transformants on 50–100 μg/mL ampicillin.</td>
</tr>
<tr>
<td>3</td>
<td>Analyze your transformants for the presence of insert by restriction digestion.</td>
</tr>
<tr>
<td>4</td>
<td>Select a transformant with the correct restriction pattern and sequence to confirm that your gene is cloned in the correct orientation.</td>
</tr>
<tr>
<td>5</td>
<td>Cotransfect your pcDNA™5/FRT construct and pOG44 into the Flp-In™ host cell line using your own method of choice and select for hygromycin resistant clones (see the Flp-In™ System manual for more information).</td>
</tr>
<tr>
<td>6</td>
<td>Assay for expression of the gene of interest.</td>
</tr>
</tbody>
</table>
Methods

Cloning into pcDNA™ 5/FRT

Introduction
A diagram is provided on the next page to help you clone your gene of interest into pcDNA™ 5/FRT. General considerations for cloning and transformation are listed below.

General Molecular Biology Techniques
For help with DNA ligations, E. coli transformations, restriction enzyme analysis, DNA sequencing, and DNA biochemistry, refer to Molecular Cloning: A Laboratory Manual (Sambrook et al., 1989) or Current Protocols in Molecular Biology (Ausubel et al., 1994).

E. coli Strain
Many E. coli strains are suitable for the propagation and maintenance of this vector. We recommend that you propagate vectors containing inserts in E. coli strains that are recombination deficient (recA) and endonuclease A deficient (endA).

For your convenience, TOP10 is available as chemically competent or electrocompetent cells from Life Technologies (page v).

Transformation Method
You may use any method of your choice for transformation. Chemical transformation is the most convenient method for many researchers. Electroporation is the most efficient and the method of choice for large plasmids.

Maintenance of Plasmids
To propagate and maintain the pcDNA™ 5/FRT and pcDNA™ 5/FRT/CAT vectors, we recommend using 10 ng of the vector to transform a recA, endA E. coli strain like TOP10, DH5α™, JM109, or equivalent. Select transformants on LB agar plates containing 50–100 µg/mL ampicillin. Be sure to prepare a glycerol stock of each plasmid for long-term storage (see page 4).

Cloning Considerations
Your insert should contain a Kozak consensus sequence with an ATG initiation codon for proper initiation of translation (Kozak, 1987; Kozak, 1990; Kozak, 1991). An example of a Kozak consensus sequence is provided below. Other sequences are possible, but the G or A at position –3 and the G at position +4 (shown in bold) illustrates the most commonly occurring sequence with strong consensus. Replacing one of the two bases at these positions provides moderate consensus, while having neither results in weak consensus. The ATG initiation codon is shown underlined.

\[(G/A)NNATGG\]

Your insert must also contain a stop codon for proper termination of your gene.

Continued on next page
Cloning into pcDNA™ 5/FRT, Continued

**Multiple Cloning Site of pcDNA™ 5/FRT**

Below is the multiple cloning site for pcDNA™ 5/FRT. Restriction sites are labeled to indicate the cleavage site. The multiple cloning site has been confirmed by sequencing and functional testing. The complete sequence of pcDNA™ 5/FRT is available for downloading from our website at www.lifetechnologies.com or from Technical Support (page 10). For a map and a description of the features of pcDNA™ 5/FRT, refer to the Appendix, pages 7–8.

<table>
<thead>
<tr>
<th>Sequence</th>
<th>Restriction Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>721</td>
<td>AAAATCAACG GGACTTTCCA AATGTCGTA ACAACTCCGC CCCATTGACG CAAATGGGGCG</td>
</tr>
<tr>
<td>781</td>
<td>GTAGGCGGTGT ACGGTTGAG GTCTATATAA GCAGAGCCTCT CCTGCTAATG AGAGAACCCA</td>
</tr>
<tr>
<td>841</td>
<td>CTGCTTACTG GCTTATGAA ATTAATACGA CCTACTATAG GGAGACCAA GCGGCTAGGC</td>
</tr>
<tr>
<td>901</td>
<td>GTTTAACTTT AAGCTTGGTA CGCGTCTCGG ATCCACTAGT CCAGTGGTG GGAATTCTGC</td>
</tr>
<tr>
<td>961</td>
<td>AGATATCCAG CACAGTGGCG CGCGTCTCGG TCTAGAGGGC CCGTTTAAAC CCGCTGATCA</td>
</tr>
<tr>
<td>1021</td>
<td>GCCTGACTGT TGCCCTCTAG TTGCCAGCAA TCTGTTGTCTT GCCCCTCCCA CGTGCCCTCC</td>
</tr>
</tbody>
</table>

*Note: there are two Pme I sites and two BstX I sites in the polyclinker.

**E. coli Transformation**

Transform your ligation mixtures into a competent recA, endA E. coli strain (e.g., TOP10, DH5α™) and select on LB agar plates containing 50–100 µg/mL ampicillin. Select 10–20 clones and analyze for the presence and orientation of your insert.

We recommend that you sequence your construct to confirm that your gene is in the correct orientation for expression and contains an ATG initiation codon and a stop codon. To sequence your construct, we suggest using the T7 Promoter and BGH Reverse primer sequences. See page 4 for sequences and location of primer binding sites. For your convenience, Life Technologies offers the T7 Promoter Primer (page v) as well as custom primer services. For more information on custom primer services, visit www.lifetechnologies.com or contact Technical Support (page 10).

**Preparing a Glycerol Stock**

Once you have identified the correct clone, purify the colony and make a glycerol stock for long-term storage. You should keep a DNA stock of your plasmid at ~20°C.

- Streak the original colony out on an LB plate containing 50 µg/mL ampicillin. Incubate the plate at 37°C overnight.
- Isolate a single colony and inoculate into 1–2 mL of LB containing 50 µg/mL ampicillin.
- Grow the culture to mid-log phase (OD_{600} = 0.5–0.7).
- Mix 0.85 mL of culture with 0.15 mL of sterile glycerol and transfer to a cryovial.
- Store at ~80°C.
Transfection

Introduction

Once you have cloned your gene of interest into pcDNA™5/FRT and have prepared clean plasmid preparations of your pcDNA™5/FRT construct and pOG44, you are ready to cotransfect the plasmids into your mammalian Flp-In™ host cell line to generate your stable Flp-In™ expression cell line. We recommend that you include the pcDNA™5/FRT/CAT positive control vector and a mock transfection (negative control) to evaluate your results. General information about transfection and selection is provided below. Specific guidelines and protocols for generation of the Flp-In™ expression cell line can be found in the Flp-In™ System manual.

For detailed information about pOG44 and generation of the Flp-In™ host cell line, refer to the Flp-In™ System manual.

Plasmid Preparation

Plasmid DNA for transfection into eukaryotic cells must be very clean and free from phenol and sodium chloride. Contaminants will kill the cells, and salt will interfere with lipid complexing, decreasing transfection efficiency. We recommend isolating plasmid DNA using the S.N.A.P.™ MiniPrep Kit (10–15 μg DNA, Catalog No. K1900-01), the S.N.A.P.™ MidiPrep Kit (10–200 μg DNA, Catalog No. K1910-01), or CsCl gradient centrifugation.

Positive Control

pcDNA™5/FRT/CAT is provided as a positive control vector for mammalian cell transfection and expression (see page 9) and may be used to assay for recombinant protein expression levels in your Flp-In™ expression cell line. Cotransfection of the positive control vector and pOG44 into your Flp-In™ host cell line allows you to generate a stable cell line expressing chloramphenicol acetyl transferase (CAT) at the same genomic locus as your gene of interest. If you have several different Flp-In™ host cell lines, you may use the pcDNA™5/FRT/CAT control vector to compare protein expression levels between the various cell lines.

Continued on next page
Transfection, Continued

Assay for CAT Protein

The CAT protein expressed from the pcDNA™5/FRT/CAT control plasmid is approximately 32 kDa in size. You may assay for CAT expression by ELISA assay, Western blot analysis, fluorometric assay, or radioactive assay (Ausubel et al., 1994; Neumann et al., 1987). For Western blot analysis, you may use CAT Antiserum available from Life Technologies for detection. Other commercial kits to assay for CAT protein are available.

Hygromycin B

The pcDNA™5/FRT vector contains the hygromycin resistance gene (Gritz & Davies, 1983) for selection of transfectants with the antibiotic, hygromycin B (Palmer et al., 1987). When added to cultured mammalian cells, hygromycin B acts as an aminocyclitol to inhibit protein synthesis. Hygromycin B liquid is supplied with the Flp-In™ Complete System and is also available separately from Life Technologies. For instructions to handle and store hygromycin B, refer to the Flp-In™ System manual.

Determination of Hygromycin Sensitivity

Before generating a stable cell line expressing your protein of interest (Flp-In™ expression cell line), we recommend that you generate a kill curve to determine the minimum concentration of hygromycin required to kill your untransfected Flp-In™ host cell line. Generally, concentrations between 10 and 400 μg/mL hygromycin are required for selection of most mammalian cell lines. General guidelines for performing a kill curve are provided in the Flp-In™ System manual.

Generation of Flp-In™ Expression Cell Lines

Refer to the Flp-In™ System manual for detailed guidelines and instructions to cotransfect your pcDNA™5/FRT construct and pOG44 into the Flp-In™ host cell line to generate stable Flp-In™ expression cell lines.
Appendix

Map of pcDNA™ 5/FRT Vector

The figure below summarizes the features of the pcDNA™5/FRT vector. Note that the hygromycin resistance gene lacks a promoter and its native ATG start codon. Transfection of the pcDNA™5/FRT plasmid alone into mammalian cells will not confer hygromycin resistance to the cells. The complete nucleotide sequence for pcDNA™5/FRT is available for downloading from our website at www.lifetechnologies.com or by contacting Technical Support (page 10).

Comments for pcDNA5/FRT 5070 nucleotides

CMV promoter: bases 232-819
CMV forward priming site: bases 769-789
T7 promoter/priming site: bases 863-882
Multiple cloning site: bases 895-1010
BGH reverse priming site: bases 1022-1039
BGH polyadenylation signal: bases 1028-1252
FRT site: bases 1536-1583
Hygromycin resistance gene (no ATG): bases 1591-2611
SV40 early polyadenylation signal: bases 2743-2873
pUC origin: bases 3256-3929 (complementary strand)
bla promoter: bases 4935-5033 (complementary strand)
Ampicillin (bla) resistance gene: bases 4074-4934 (complementary strand)
Features of pcDNA™ 5/FRT Vector

pcDNA™ 5/FRT is a 5070 bp vector that expresses your gene of interest under the control of the human CMV promoter. The table below describes the relevant features of pcDNA™ 5/FRT. All features have been functionally tested.

<table>
<thead>
<tr>
<th>Feature</th>
<th>Benefit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human cytomegalovirus (CMV) immediate early promoter</td>
<td>Allows high-level expression of your gene of interest (Andersson et al., 1989; Boshart et al., 1985; Nelson et al., 1987).</td>
</tr>
<tr>
<td>CMV Forward priming site</td>
<td>Allows sequencing in the sense orientation.</td>
</tr>
<tr>
<td>T7 promoter/priming site</td>
<td>Allows in vitro transcription in the sense orientation and sequencing through the insert.</td>
</tr>
<tr>
<td>Multiple cloning site</td>
<td>Allows insertion of your gene of interest.</td>
</tr>
<tr>
<td>pBGH Reverse priming site</td>
<td>Allows sequencing of the non-coding strand.</td>
</tr>
<tr>
<td>Bovine growth hormone (BGH) polyadenylation signal</td>
<td>Allows efficient transcription termination and polyadenylation of mRNA (Goodwin &amp; Rottman, 1992).</td>
</tr>
<tr>
<td>Flp Recombination Target (FRT) site</td>
<td>Encodes a 34 bp (+14 bp of non-essential) sequence that serves as the binding and cleavage site for Flp recombinase (Gronostajski &amp; Sadowski, 1985; Jayaram, 1985; Senecoff et al., 1985).</td>
</tr>
<tr>
<td>Hygromycin resistance gene (no ATG)</td>
<td>Allows selection of stable transfectants in mammalian cells (Gritz &amp; Davies, 1983) when brought in frame with a promoter and an ATG initiation codon through Flp recombinase-mediated recombination via the FRT site.</td>
</tr>
<tr>
<td>SV40 early polyadenylation signal</td>
<td>Allows efficient transcription termination and polyadenylation of mRNA.</td>
</tr>
<tr>
<td>pUC origin</td>
<td>Allows high-copy number replication and growth in E. coli.</td>
</tr>
<tr>
<td>bla promoter</td>
<td>Allows expression of the ampicillin (bla) resistance gene.</td>
</tr>
<tr>
<td>Ampicillin (bla) resistance gene (β-lactamase)</td>
<td>Allows selection of transformants in E. coli.</td>
</tr>
</tbody>
</table>
pcDNA™ 5/FRT/CAT Vector

Description

pcDNA™ 5/FRT/CAT is a 5858 bp control vector containing the gene for chloramphenicol acetyl transferase (CAT). This vector was constructed by ligating a 0.7 kb Xho I-Apa I fragment containing the CAT gene into the Xho I-Apa I site of pcDNA™ 5/FRT. The CAT protein expressed from pcDNA™ 5/FRT/CAT is approximately 32 kDa in size.

Map of pcDNA™ 5/FRT/CAT

The figure below summarizes the features of the pcDNA™ 5/FRT/CAT vector. The complete nucleotide sequence for pcDNA™ 5/FRT/CAT is available for downloading from our website at www.lifetechnologies.com or from Technical Support (page 10).

Comments for pcDNA5/FRT/CAT

5858 nucleotides

CMV promoter: bases 232-819
CMV forward priming site: bases 769-789
T7 promoter/priming site: bases 863-882
Chloramphenicol acetyl transferase (CAT) gene: bases 1026-1685
BGH reverse priming site: bases 1810-1827
BGH polyadenylation signal: bases 1816-2040
FRT site: bases 2324-2371
Hygromycin resistance gene (no ATG): bases 2379-3399
SV40 early polyadenylation signal: bases 3531-3661
pUC origin: bases 4044-4717 (complementary strand)
bla promoter: bases 5723-5821 (complementary strand)
Ampicillin (bla) resistance gene: bases 4862-5722 (complementary strand)
Technical Support

Obtaining Support

For the latest services and support information for all locations, go to www.lifetechnologies.com

At the website, you can:

- Access worldwide telephone and fax numbers to contact Technical Support and Sales facilities
- Search through frequently asked questions (FAQs)
- Submit a question directly to Technical Support (techsupport@lifetech.com)
- Search for user documents, SDSs, vector maps and sequences, application notes, formulations, handbooks, certificates of analysis, citations, and other product support documents
- Obtain information about customer training
- Download software updates and patches

Safety Data Sheets (SDS)

Safety Data Sheets (SDSs) are available at www.lifetechnologies.com/support

Certificate of Analysis

The Certificate of Analysis provides detailed quality control and product qualification information for each product. Certificates of Analysis are available on our website. Go to www.lifetechnologies.com/support and search for the Certificate of Analysis by product lot number, which is printed on the box.

Limited Product Warranty

Life Technologies Corporation and/or its affiliate(s) warrant their products as set forth in the Life Technologies’ General Terms and Conditions of Sale found on Life Technologies’ website at www.lifetechnologies.com/termsandconditions. If you have any questions, please contact Life Technologies at www.lifetechnologies.com/support.
References


©2012 Life Technologies Corporation. All rights reserved. The trademarks mentioned herein are the property of Life Technologies Corporation or their respective owners. Zeocin is a registered trademark of Cayla Sarl.
LIFE TECHNOLOGIES CORPORATION AND/OR ITS AFFILIATE(S) DISCLAIM ALL WARRANTIES WITH RESPECT TO THIS DOCUMENT, EXPRESSED OR IMPLIED, INCLUDING BUT NOT LIMITED TO THOSE OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. TO THE EXTENT ALLOWED BY LAW, IN NO EVENT SHALL LIFE TECHNOLOGIES AND/OR ITS AFFILIATE(S) BE LIABLE, WHETHER IN CONTRACT, TORT, WARRANTY, OR UNDER ANY STATUTE OR ON ANY OTHER BASIS FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING BUT NOT LIMITED TO THE USE THEREOF.